Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study of real-world effectiveness, safety and tolerability of perampanel in epilepsy patients with focal-onset and generalized-onset seizures

Trial Profile

A retrospective study of real-world effectiveness, safety and tolerability of perampanel in epilepsy patients with focal-onset and generalized-onset seizures

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Generalised seizures; Seizures
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 26 Apr 2022 Results assessing effectiveness of adjunctive brivaracetam (BRV) in adults with focal seizures as measured by retention, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
  • 26 Apr 2022 Results assessing perampanel (PER) when used as monotherapy in everyday clinical practice, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
  • 18 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top